What you may have missed from TCT 2023

Healio and Cardiology Today have aggregated news you may have missed from TCT 2023 in San Francisco.

News from TCT included reaffirmation of the safety of TAVR among patients at low surgical risk; the feasibility of aspirin cessation 1 month after drug-eluting stent implant; sustained BP lowering observed after ultrasound renal denervation; and more.

TAVR continues to be comparable to surgery in patients at low surgical risk

In patients with severe aortic stenosis at low surgical risk, transcatheter aortic valve replacement was linked with similar long-term outcomes to surgery, according to two trials presented at TCT 2023. Read more

Stopping aspirin 1 month after drug-eluting stent implantation feasible for patients with ACS

In patients with ACS, stopping aspirin for ticagrelor monotherapy within 1 month of receiving a drug-eluting stent did not increase adverse CV and bleeding events compared with 12 months of dual antiplatelet therapy. Read more

Transcatheter tricuspid valve replacement feasible with acceptable safety profile

Transcatheter tricuspid valve replacement was feasible and had a lower-than-expected rate of safety events, according to an analysis of the first 150 patients in the TRISCEND II pivotal trial. Read more

Drug-coated balloon bests uncoated balloon for coronary in-stent restenosis in AGENT IDE trial

A paclitaxel-coated balloon was superior to conventional balloon angioplasty for treatment of coronary in-stent restenosis, according to the results of the AGENT IDE trial. Read more

New RADIANCE data: ‘Durable’ BP lowering, fewer meds after ultrasound renal denervation

A new pooled analysis showed a maintained BP-lowering effect with fewer added medications after treatment with an ultrasound renal denervation system compared with a sham procedure, a speaker reported at TCT 2023. Read more

BIOSTEMI: 5-year data show superiority for biodegradable SES vs. durable EES

A biodegradable polymer sirolimus-eluting stent remained superior to a durable polymer everolimus-eluting stent for treating STEMI at 5 years, a difference driven by lower rates of ischemia-driven repeat revascularizations. Read more

Catheter-directed thrombolysis for PE confers less bleeding vs. mechanical thrombectomy

In the REAL-PE study of a real-world population of patients with pulmonary embolism, catheter-directed thrombolysis was associated with reduced risk for major bleeding compared with mechanical thrombectomy. Read more

Bioresorbable scaffold superior to angioplasty for treating chronic limb-threatening ischemia

An everolimus-eluting bioresorbable scaffold was superior to angioplasty for the treatment of patients with chronic limb-threatening ischemia, according to the results of the LIFE-BTK trial. Read more

New data confirm benefit of TEER for severe tricuspid regurgitation

In a pooled analysis, transcatheter edge-to-edge repair benefited patients with severe tricuspid regurgitation, even those with complex anatomies. Read more

Concomitant left atrial appendage occlusion, TAVR an option for some with AF: WATCH-TAVR

Left atrial appendage occlusion at the time of TAVR provides a noninferior treatment option to TAVR plus medical therapy in patients with severe aortic stenosis and atrial fibrillation. Read more